Aktuellt
SENASTE
Redeye comments on Medivir's Q2 report. The main event in the quarter was the presentation of an estimated mean TTP of 10.8 months for fostrox in liver cancer. The next catalyst will be updated fostrox data at ESMO in mid-September.
LÄS MER
